Paradigm has partnered with Bristol Myers Squibb to create an end-to-end clinical trial operational model for design, patient recruitment and data collection.

Initially, the collaboration will focus on oncology and will further expand to cover other therapeutic areas.

In this partnership, Bristol Myers Squibb will be able to enrol patients through providers across the Paradigm Network of health systems who serve different groups.

These health systems already utilise the software from Paradigm to reduce the burden of clinical trial recruitment as well as operations.

The administrative challenges of running clinical trials have led to limited accessibility and uneven patient enrolment.

Presently, less than 5% of cancer patients participate in clinical trials during their treatment journeys.

This process delayed the introduction of new treatments on the market and millions of individuals who may benefit from trials are not able to take part.

In response to this challenge, Paradigm has decided to create a new clinical trial operating ecosystem.

Paradigm and Bristol Myers Squibb are designing trials whose protocol requirements meet the practical constraints of community health provider organisations.

Initially, Paradigm introduced its clinical trial software platform to community healthcare providers, who provided care for patients with cancer and other severe conditions, as well as served populations that mirror the overall US demographics.

Paradigm CEO Kent Thoelke said: “We fundamentally believe every patient deserves the best possible care, which should include the evaluation for participation in clinical research. Working with a leader like Bristol Myers Squibb helps scale equitable access for patients today.

“In the process, we aim to help Bristol Myers Squibb speed up recruitment, attract a more diverse patient population, reduce provider burden and more rapidly complete trials to increase access to potentially helpful therapies in the future.”